Author:
Effat Heba,Abosharaf Hamed A.,Radwan Aliaa M.
Abstract
AbstractBreast cancer therapy options are limited due to its late diagnosis and poor prognosis. Doxorubicin is the fundamental therapy approach for this disease. Because chemotherapy has numerous adverse effects, the scope of the existing research was to appraise the synergetic effect of doxorubicin and naringin and explore the underlying mechanism. The cytotoxicity of doxorubicin and naringin on MCF-7 was monitored. Furthermore, the expression of STAT3 and JAK1 as well as the apoptotic and metastatic related genes (Bax, Bcl-2, Survivin, and VEGF) were conducted by immunoblotting assay and qRT-PCR. In addition, a wound healing test was utilized to appraise the migration and metastasis of MCF-7. Our results revealed that naringin and doxorubicin had a synergetic inhibitory influence on MCF-7 cells growth and migration. The synergetic action of doxorubicin and naringin effectively hindered the expression of STAT3, JAK1, Bcl-2, Survivin, and VEGF, with a boost in the level of Bax compared to cells treated with either doxorubicin or naringin. In conclusion, our findings imply that combining doxorubicin with naringin may be a favorable strategy for inhibiting the growth of breast cancer.
Publisher
Springer Science and Business Media LLC
Reference43 articles.
1. Abdelaziz, A. H. et al. Breast cancer awareness among Egyptian women and the impact of caring for patients with breast cancer on family caregivers’ knowledge and behaviour. Res. Oncol. 17, 1–8 (2021).
2. Wang, X., Zhang, H. & Chen, X. Drug resistance and combating drug resistance in cancer. CDR (Alhambra Calif.) 2, 141–160. https://doi.org/10.20517/cdr.2019.10 (2019).
3. Alfarouk, K. O. et al. Resistance to cancer chemotherapy: Failure in drug response from ADME to P-gp. Cancer Cell Int. 15, 1–13 (2015).
4. Mohajeri, M. & Sahebkar, A. Protective effects of curcumin against doxorubicin-induced toxicity and resistance: A review. Crit. Rev. Oncol. Hematol. 122, 30–51 (2018).
5. Bayat Mokhtari, R. et al. Combination therapy in combating cancer. Oncotarget 8, 38022–38043. https://doi.org/10.18632/oncotarget.16723 (2017).